Seung -Cheol Lee1, Eric A. Mellon1, Harish Poptani1, Edward James Delikatny1, Jerry David Glickson1
1Dept of Radiology, University of Pennsylvania, Philadelphia, PA, USA
Previously weve shown in a human lymphoma xenograft model that in vivo MRS detected lactate is a very early marker of response to either CHOP or R-CHOP therapy. Last year weve presented clinical scanner version of the lactate detection sequence (Hadamard-SelMQC-CSI) in the phantom studies. This year we applied the clinical scanner version of the lactate sequence to monitoring early response to R-CHOP therapy in a non-Hodgkins lymphoma patient.